Zhengda Sunny will take more than $3 billion varieties with Howson, Colum siege original research drugs

Recently, Zhengda Tianqing Pharmaceuticals to imitate the 4 categories of reported Engele net tablets into the administrative approval stage.
2019 net global sales of more than 3 billion U.S. dollars, there are currently Howson, Colum's products have been approved for production and evaluation, breaking the monopoly of the original drug.
Source: The National Drug Administration's official website, Engel net is a sodium glucose co-transporter 2 (SGLT-2) inhibitor developed jointly by Grigg Ingham and Lilly to improve blood sugar control in patients with type 2 diabetes in conjunction with diet control and exercise.
Net Global Sales Source: Minnenet Multinational Listed Company Sales Ku Nglinet was approved by the FDA for listing as early as August 2014, with Milnenet data showing global sales of more than $3 billion in 2019; In 2019, Engele was approved to enter the domestic market, with total sales of more than 30 million yuan in urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) and china's urban physical pharmacy terminals in 2019, up 831.29 percent year-on-year.
In addition to the original research manufacturers, the current domestic market has Howson, Colum two enterprises have Engele net film production approval, both enterprises' products are reported in a new classification, approved after production as if through a consistent evaluation.
Zhengda Tianqing pharmaceutical products have entered the administrative approval stage, sprinting home-made 3rd.
In addition, there are Yangzijiang, Osaikang, Jiangsu Wanbang bio-chemical and other enterprises with new classification of products, is still in the "in the review and approval (in the drug review center)" state.